Bronchitis vs. asthma: Differences in symptoms, causes, and treatment options – Bel Marra Health


Bel Marra Health

Bronchitis vs. asthma: Differences in symptoms, causes, and treatment options
Bel Marra Health
An asthmatic attack will not trigger bronchitis, but a bout of bronchitis in an asthmatic patient can cause a flare-up of the asthma symptoms. In fact, this happens so often that many young medical students often ask the question, “can bronchitis lead

View full post on asthma – Google News

Asthma vs. COPD: Differences in symptoms, causes, and treatment options – Bel Marra Health


Bel Marra Health

Asthma vs. COPD: Differences in symptoms, causes, and treatment options
Bel Marra Health
Asthma vs. COPD: Differences in symptoms, causes, and treatment options Asthma and chronic obstructive pulmonary disease (COPD) are both respiratory conditions that are chronic and affect a person's breathing. With many shared similarities, the two can …

View full post on asthma – Google News

New Data From GAP Landmark Trial Confirm GRAZAX® Prevents Asthma Symptoms in Children – PR Newswire (press release)

New Data From GAP Landmark Trial Confirm GRAZAX® Prevents Asthma Symptoms in Children
PR Newswire (press release)
The data, presented at the 2016 Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Vienna, confirm that GRAZAX® can prevent asthma symptoms, as well as offering sustained relief from grass allergy symptoms.

and more »

View full post on asthma – Google News

New Data From GAP Landmark Trial Confirm GRAZAX® Prevents Asthma Symptoms in Children – PR Newswire UK (press release)

New Data From GAP Landmark Trial Confirm GRAZAX® Prevents Asthma Symptoms in Children
PR Newswire UK (press release)
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today presented new data from the GRAZAX® Asthma Prevention (GAP) trial with GRAZAX®, ALK's allergy immunotherapy tablet against grass pollen allergy. The data, presented at the 2016 Annual Congress …

and more »

View full post on asthma – Google News

Persistent nasal symptoms and mediator release after continuous pollen exposure in an environmental challenge chamber.

Related Articles

Persistent nasal symptoms and mediator release after continuous pollen exposure in an environmental challenge chamber.

Ann Allergy Asthma Immunol. 2016 Jun 1;

Authors: Okuma Y, Okamoto Y, Yonekura S, Iinuma T, Sakurai T, Hamasaki S, Ohki Y, Yamamoto H, Sakurai D

Abstract
BACKGROUND: Immediate- and late-phase reactions are associated with nasal symptoms of patients with allergic rhinitis.
OBJECTIVE: To examine the symptoms and mediators released after continuous allergen exposure in an environmental challenge chamber (ECC).
METHODS: Fifteen patients with Japanese cedar pollinosis were enrolled in this study and continuously exposed to cedar pollen at a concentration of 8,000 grains/m(3) for 3 hours in an ECC. Nasal function tests were performed, and nasal secretions were collected before pollen exposure (0 hour), immediately after exiting the ECC (3 hours), and 6 hours after exiting the ECC (9 hours). Symptom scores were recorded every 30 minutes in the ECC and every 3 hours after exiting the ECC. The frequency of sneezing and nose blowing also was monitored.
RESULTS: The severity of symptoms in the ECC peaked approximately 2 hours after the beginning of pollen exposure and continued more than 6 hours after leaving the ECC. Concentrations of histamine, tryptase, interleukins 5, 3, 33, and 31, and substance P increased over time, whereas that of nasal fractional exhaled nitric oxide decreased.
CONCLUSION: Various mediators are released during continuous allergen exposure, which subsequently induce persistent nasal symptoms. Effective treatment is required to control the intense inflammation observed after allergen exposure.

PMID: 27263086 [PubMed – as supplied by publisher]

View full post on pubmed: asthma